CHR-P programme
NWPharmaTech’s clinical high-risk for psychosis (CHR-P) programme is investigating NWPT-SM32300 — an investigational CBD micellar-emulsion softgel — with Professor Scott Woods as programme lead.
Investigational — effectiveness in this population has not been established.
Image caption: Conceptual neural motif for early CNS research — not evidence of targeting or clinical benefit.
Clinical need
Clinical high risk for psychosis (CHR-P) identifies people with elevated transition risk relative to the general population. It is not a diagnosis of schizophrenia, and it does not mean any individual will inevitably develop psychosis. An updated meta-analysis estimated that about one in four people identified as CHR-P (pooled estimate, 25%) developed psychosis within three years — while most do not (Salazar de Pablo et al., 2021, JAMA Psychiatry). UK NICE guidance emphasises specialist assessment and psychological care — and does not recommend antipsychotics to prevent psychosis in the at-risk group.
Current programme
Status: planned Phase 2B · investigational
Investigational NWPT-SM32300 (300 mg CBD micellar-emulsion softgel) in people at clinical high risk: dose response, symptoms, safety and tolerability — approximately 328 participants, 12 weeks + week 16 follow-up. Effectiveness has not been established. Prevention is not the current primary aim.
Scientific leadership
Programme scientific leadership for CHR-P and related psychiatric development. Roles are individual scientific and company roles — not institutional endorsements of this website or any financing vehicle.
CHR-P programme lead Individual capacity
Clinical high-risk-for-psychosis expertise supporting early identification, assessment, and intervention research. Yale University does not sponsor or endorse this website, the DAO, or any financing vehicle.
Partner & Chief Scientific Officer
Company scientific leadership for NWPharmaTech’s research and development agenda, including the investigational CHR-P candidate.
Lead — Schizophrenia Programme
Senior psychiatric leadership for the company’s schizophrenia development strategy and clinical programme.
Latest updates
Educational notes on the science and proposed approach — not announcements of new clinical results or fundraising totals.
CHR-P, current care, and why intervening earlier is a research priority.
Published 22 Sep 2026 · Evergreen Programme updatesPlain-language overview of the proposed design — not a results announcement.
Published 21 Sep 2026 Science explainedWhat the CHR-P workstream is designed to learn — and what remains open today.
Published 20 Sep 2026 · EvergreenFunding overview
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
Any ~US$10 million figure is a planning target only — not money already raised, and not a claim that catalytic capital fully funds the Phase 2B programme.
